))
Arrhythmic mitral valve prolapse: where do we stand?
Manage episode 416909348 series 3560495
内容由European Society of Cardiology提供。所有播客内容（包括剧集、图形和播客描述）均由 European Society of Cardiology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
With Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.
In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.
24集单集
分享
